# Semaglutide extended lifespan in female mice > Late-life treatment increased median lifespan and preserved several functions in one mouse strain, but it has not been shown to slow human aging or extend human life. _Source: Nature research article, checked against PubMed, Crossref, OpenAlex and the journal source data · 2026-09-08 · 7 min read · Verified against primary sources_ Canonical: https://iyu.app/e/semaglutide-lifespan-aged-female-mice ## The 60-second version Late-life semaglutide increased median lifespan and preserved several functions in aged female C57BL/6 mice. **Key points** - The lifespan cohort included 39 control and 40 treated mice; median survival was 742 versus 834 days. - Food intake fell 24%, and a separate matched comparison found overlap with calorie restriction as well as different feeding physiology. - Behavioral, metabolic and molecular findings came from separate, often small cohorts and need independent replication. - No human aging or lifespan outcome was tested, and the university disclosed a related patent application. **Verdict.** A credible preclinical longevity signal in one female mouse model is not evidence that semaglutide extends human life. ## Full explainer > **⚑ Caveat:** Evidence boundary: this was an experiment in aged female mice of one inbred strain. It did not test human lifespan, and it does not support prescribing semaglutide for anti-aging use. ### Main result — Median lifespan increased by 92 days in mice Researchers started treatment in **20-month-old female C57BL/6 mice**. Thirty-nine controls received saline and 40 mice received semaglutide at 10 nmol per kilogram by daily subcutaneous injection for the rest of life. Median lifespan was **742 days** in controls and **834 days** with semaglutide. The 92-day difference is about 12.4% of the control median. The study used a log-rank survival comparison and counted both natural deaths and prespecified humane endpoints as deaths. - **39 vs 40** — control and treated mice in the lifespan cohort - **+92 days** — difference between group median lifespans - **24%** — reduction in food intake with semaglutide ### Comparison — The effect overlapped with calorie restriction Because semaglutide reduced food intake, the team compared it directly with matched 24% calorie restriction in another five-month experiment. That cohort had 10 mice in each of three groups: saline, semaglutide and calorie restriction. Both interventions reduced fat and slowed decline on several functional tests. They did not create the same physiological state: calorie-restricted mice ate quickly and then fasted, whereas semaglutide-treated mice ate more gradually. Some exploratory, spatial-memory and glucose trajectories favored semaglutide, but the small mouse cohort cannot establish an extra benefit in humans. - **Lifespan cohort:** 39 controls and 40 treated female mice; treatment continued for life. - **Longitudinal comparison:** 10 mice per group; saline, semaglutide or matched calorie restriction for five months. - **Other assays:** Separate cohorts of 5 to 10 mice per group measured behavior, tissue and molecular outcomes. - **Human evidence:** No human aging or lifespan endpoint was tested. ### Mechanism — Multiple aging-related measures moved together Separate cohorts showed better performance on several movement, motor, muscle, spatial-memory and glucose tests. Tissue analyses reported lower inflammatory and senescence markers, improved mitochondrial and protein-homeostasis measures, and shifts in nutrient sensors and conserved aging regulators. This broad pattern makes the survival finding more biologically coherent. It does not prove one master mechanism. Many secondary experiments used small samples, including five mice per group for liver RNA sequencing, and multiple endpoints increase the need for independent replication. ### Study quality — Randomization and blinding strengthen the mouse result Mice were randomized. Data collection and analysis were blinded to treatment except for calorie-restricted animals, whose feeding schedule was visible. Most experiments were repeated twice; the RNA-sequencing experiment was not, although its themes were checked with other assays. - **Sex and strain:** only female C57BL/6 mice were tested; male mice and genetically diverse animals may respond differently. - **Scale:** the survival cohort was moderate, while several mechanistic cohorts contained only 5 to 10 mice per group. - **Translation:** mouse aging, dosing and daily injections do not define a human longevity regimen. - **Safety:** no attributable adverse effects were observed in monitored mouse endpoints, which is not equivalent to human long-term safety. ### Interests — A related patent was disclosed The Regents of the University of California filed a patent application on GLP-1 receptor agonists for healthy aging. The study also reported US National Institute on Aging grants. The disclosure does not erase the result, but it makes independent replication especially important. > The paper supports a late-life intervention in female mice, not a longevity prescription for people. ### Takeaway — What should happen next The useful next tests are replication in males and other mouse strains, studies of dose and treatment withdrawal, and confirmation by independent laboratories. Human claims would require long-term randomized studies designed around aging-related outcomes. Until then, semaglutide should not be used for longevity outside approved indications and clinical supervision. ## Primary sources - [Telegram post 1472](https://t.me/CNSmydream/1472) - [Nature research article](https://www.nature.com/articles/s41586-026-10940-7) - [PubMed record (PMID 42686906)](https://pubmed.ncbi.nlm.nih.gov/42686906/) - [Crossref DOI record](https://api.crossref.org/works/10.1038/s41586-026-10940-7) - [OpenAlex record](https://openalex.org/W7205709427) --- _Published by iyu (https://iyu.app) — the day's AI news, checked against primary sources and rewritten in plain language. Free to quote with attribution and a link to the canonical URL._